Barclays lowered the firm’s price target on HCA Healthcare (HCA) to $390 from $416 and keeps an Overweight rating on the shares post the Q2 report. The firm says the company’s CEO expressed confidence in navigating 2026 and beyond.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- Hold Rating for HCA Healthcare Amid Strong Q2 Results and Future Headwinds Concerns
- HCA Healthcare Reports Strong Q2 2025 Results
- HCA Healthcare: Mixed Financial Performance and Volume Growth Concerns Lead to Hold Rating
- Morning Movers: Intel lower following second quarter earnings
- HCA Healthcare Reports Strong Q2 2025 Financial Results